‘Pay-for-performance’ may lead to higher risk for robotic prostate surgery patients

30 marzo 2015

A ‘perverse disincentive’ for hospitals that have invested in expensive technology for robotic surgery may be jeopardizing prostate cancer patients who seek out the procedure, concluded a new study. The study, which compared complication rates in hospitals with low volumes of robot-assisted radical prostatectomies to institutions with high volumes of the procedure, suggested that current pay-for-performance healthcare models are to blame.